Canaccord Genuity Morning Coffee on Dendreon (DNDN) and Johnson & Johnson (JNJ): Honeydew Sized Prostate
Tweet
Share
E-mailGet Alerts DNDN Hot Sheet
Price: $0.13 --0%
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
2 Buy, 15 Hold, 9 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity Morning Coffee on Dendreon (Nasdaq: DNDN) and Johnson & Johnson (NYSE: JNJ)
“I've got a prostate the size of a honeydew and a head full of bad memories.” – Maury Ballstein, Zoolander.
Shares of Dendreon continued to slide on Friday following Johnson & Johnson’s Wednesday announcement regarding its prostate cancer treatment, Zytiga, which competes with Dendreon’s Provenge solution. There was an early halt for efficacy of a a Phase III trail evaluating Zytiga in patients fitting the same clinical criteria specified for Provenge. Canaccord Genuity Life Sciences Analyst George Farmer believes this announcement came earlier than expected and raises the perception of competitive threats to Provenge sales. He believes the data from the trial, details of which have not been disclosed, will be ready by the American Society of Clinical Oncology’s annual June meeting and will be critical in assessing the prostate cancer treatment competitive landscape. Provenge demonstrated a 4.1-month OS benefit in this patient population, with without symptomatic relief that he believes Zytuiga will show. Farmer believes shares of Dendreon could remain under pressure into the June data presentation. That said, he continues to see more upside than downside at current trading levels on his view of $1-billion peak Provenge sales achievable in 2021, supported by his assessment of broad awareness and desire to prescribe Provenge among physicians and an improving reimbursement environment.
This morning, DNDN is trading flat on the session. JNJ is up about 0.27%.
“I've got a prostate the size of a honeydew and a head full of bad memories.” – Maury Ballstein, Zoolander.
Shares of Dendreon continued to slide on Friday following Johnson & Johnson’s Wednesday announcement regarding its prostate cancer treatment, Zytiga, which competes with Dendreon’s Provenge solution. There was an early halt for efficacy of a a Phase III trail evaluating Zytiga in patients fitting the same clinical criteria specified for Provenge. Canaccord Genuity Life Sciences Analyst George Farmer believes this announcement came earlier than expected and raises the perception of competitive threats to Provenge sales. He believes the data from the trial, details of which have not been disclosed, will be ready by the American Society of Clinical Oncology’s annual June meeting and will be critical in assessing the prostate cancer treatment competitive landscape. Provenge demonstrated a 4.1-month OS benefit in this patient population, with without symptomatic relief that he believes Zytuiga will show. Farmer believes shares of Dendreon could remain under pressure into the June data presentation. That said, he continues to see more upside than downside at current trading levels on his view of $1-billion peak Provenge sales achievable in 2021, supported by his assessment of broad awareness and desire to prescribe Provenge among physicians and an improving reimbursement environment.
This morning, DNDN is trading flat on the session. JNJ is up about 0.27%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'
- DA Davidson Starts Everus (ECG) at Buy
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
